

Review Article

Class II phosphatidylinositol 3-kinase isoforms in vesicular trafficking

 Kazuaki Yoshioka

Department of Physiology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8640, Japan

Correspondence: Kazuaki Yoshioka (yoshioka@med.kanazawa-u.ac.jp)



Phosphatidylinositol 3-kinases (PI3Ks) are critical regulators of many cellular processes including cell survival, proliferation, migration, cytoskeletal reorganization, and intracellular vesicular trafficking. They are a family of lipid kinases that phosphorylate membrane phosphoinositide lipids at the 3' position of their inositol rings, and in mammals they are divided into three classes. The role of the class III PI3K Vps34 is well-established, but recent evidence suggests the physiological significance of class II PI3K isoforms in vesicular trafficking. This review focuses on the recently discovered functions of the distinct PI3K-C2 α and PI3K-C2 β class II PI3K isoforms in clathrin-mediated endocytosis and consequent endosomal signaling, and discusses recently reported data on class II PI3K isoforms in different physiological contexts in comparison with class I and III isoforms.

Introduction

Endocytosis is an essential process in which proteins and lipids are internalized as membrane-bound cargo in forms such as clathrin-coated vesicles, which are regulated by phosphoinositides (PIs), small G-proteins including Rabs and other proteins [1, 2]. Subcellular localization patterns of PIs are tightly controlled by the regulation of lipid kinases and lipid phosphatases. Among these, phosphatidylinositol 3-kinases (PI3Ks) catalyze the transfer of the γ -phosphate group of adenosine triphosphates to the D3 position of their inositol ring and control diverse processes including cell proliferation, migration, cytoskeletal reorganization, and vesicular trafficking [1–3]. Yeasts have a single PI3K homolog called Vps34 which mainly regulates autophagy [4, 5], whereas higher eukaryotes have multiple PI3K isoforms.

In mammals, PI3Ks are categorized into three classes based on their substrate specificity [3]. Class I PI3Ks directly engage in signaling downstream of plasma membrane-bound receptors, whereas class II and III PI3Ks primarily regulate vesicular trafficking and subsequently regulate cellular signaling. Ligand binding triggers the activation and internalization of signaling receptors from the plasma membrane into early endosomes, where receptors are sorted to the late endosomes/lysosomes for degradation or recycling back to the plasma membrane [6–8]. Numerous recent studies indicate that receptor signaling continues on endosomes after receptor endocytosis [9–11]. We recently demonstrated that PI3K-C2 α and PI3K-C2 β have specific redundant cellular functions pertaining to clathrin-mediated endocytosis, endosomal signaling, and the regulation of Rho-dependent smooth muscle contraction [12–16].

Herein we discuss emerging data on the isoform-specific regulation of class II PI3Ks, the coordination of membrane composition, and the regulation of intracellular signaling of class II PI3Ks. Recent reviews have mentioned an increasing relating to their intracellular functions [2, 17–19]. The current review also focuses on emerging evidence that class II PI3Ks could be used as therapeutic targets, particularly in vascular diseases.

Received: 4 January 2021
Revised: 12 February 2021
Accepted: 16 February 2021

Version of Record published:
5 March 2021

Structure and substrate specificities of class II PI3K isoforms

Class I PI3Ks have been intensely investigated, their fundamental roles have been identified, and physiological insights into class I PI3K activation and regulation have been reviewed [1–3, 20, 21]. The PI3K isoform Vps34 is conserved in yeasts and humans. It is the single class III isoform and is responsible for regulating autophagy and endo-lysosomal sorting via the respective production of phosphatidylinositol-3-monophosphate (PI(3)P) in autophagosomes and endo-lysosomes [2, 4, 5]. In mammals class II PI3Ks include PI3K-C2 α , PI3K-C2 β , and PI3K-C2 γ , which remain the least characterized PI3K subfamily [22, 23]. Class II PI3Ks have strong resistance against the pan-PI3K inhibitors wortmannin and LY294002 [24–26], and selective inhibitors of class II PI3K isoforms have not yet been developed. PI3K-C2 α and PI3K-C2 β are expressed ubiquitously, whereas PI3K-C2 γ exhibits a more restricted pattern of expression, mainly in hepatocytes [27–29]. Class II PI3Ks have a conserved C-terminal extension with the PX and C2 domains that is unique to the class II isoforms and is probably responsible for the association with PI(4,5)P₂-containing plasma membranes [30, 31] (Figure 1). Class II PI3Ks also have an extended N-terminal region with additional protein-binding regions, such as the clathrin-binding domain in PI3K-C2 α and the unique proline-rich motif in PI3K-C2 β [32, 33]. It has been suggested that clathrin can bind directly to PI3K-C2 α but not to PI3K-C2 β , which contains the ‘clathrin box motif’ consensus sequence (L[LI][DEN][LF][DE]) [34, 35] (Figure 1), although previous analysis indicates that PI3K-C2 β has an affinity for the recombinant clathrin protein *in vitro* [33, 36].

The lipid products of class II PI3Ks have been a subject of discussion, and it is now accepted that they phosphorylate both PI and PI(4)P resulting in the respective synthesis of PI(3)P and PI(3,4)P₂ [37, 38] (Figure 2A). These 3'-phosphoinositides can regulate various membrane trafficking processes and are key membrane identity markers (Figure 2B). Recent studies have demonstrated that PI3K-C2 α becomes fully active at the clathrin-coated pits (CCPs) by changing its conformation when the N-terminal clathrin-binding domain and the C-terminal PX-C2 domains, which are associated with clathrin and membrane-bound PI(4,5)P₂, respectively [31, 32]. This supports the contention that PI3K-C2 α generates PI(3,4)P₂ and primarily functions in the endocytic pits in a kinase-dependent manner. It has also been proposed that PI3K-C2 α regulates cilia formation by producing PI(3)P via the recycling endosomes, and that it activates Rab11 which is an important regulator of endosome recycling [37]. The endosomal PI(3)P pools are also involved in cellular signaling including growth factor receptor responses [12, 39], cell migration [13, 40], and insulin stimulation responses. Vps34 contributes to the production of basal cellular PI(3)P in many cell types [2]. It is believed that Vps34 is one of the main sources of cellular PI(3)P, though it is not the only source. Class II PI3Ks and lipid phosphatases presumably contribute to the maintenance of the PI(3)P pool in a cell context-dependent manner. Their distinct subcellular localization and/or complex regulation of upstream and downstream targets may affect localized PI(3)P production and represent part of a distinct PI(3)P pool that controls different types of cell signaling. The substrate specificity of PI3Ks is difficult to determine precisely, particularly given that PI(3)P and PI(3,4)P₂ are only present in trace amounts in normal resting cells and exhibit rapid turnover. Local endosomal PI(3)P levels may be derived from PI(3,4)P₂ dephosphorylation by 4'-phosphatase INPP4 during endocytosis [41]. In a recent report we postulated that the formation of PI(3,4)P₂ by PI3K-C2 α followed by 5'-phosphatase synaptojanin-1-mediated PI(4)P production from PI(4,5)P₂ at CCPs mediates TGF β 1 receptor endocytosis and TGF β 1-induced activation of Smad2/3 on endosomes [42]. The intracellular role of PI3K-C2 α in clathrin-mediated endocytosis demonstrates how sequential phosphoinositide conversion can transmit CCP formation to clathrin-coated vesicle identity.

Cellular functions of class II PI3K isoforms

At the clathrin lattice, PI3K-C2 α metabolizes PI(4,5)P₂ to PI(3,4)P₂ in cooperation with the PI-5'-phosphatases ORCL and synaptojanin-1 [35, 42]. Localized enrichments in PI(3,4)P₂ enable the recruitment of endocytic accessory proteins such as sorting nexin-9, which interact with actin-branching activator Arp2/3 and dynamin, and ultimately generate constricting force at the neck of the CCPs [43–46] (Figure 3). Endocytosis is considered an important mechanism involved in down-regulation of receptor signaling events via the internalization of ligand–receptor complexes. Notably however, evidence reported in the last two decades indicates that endocytosis can contribute to a form of intracellular signal transduction dubbed ‘endosomal signaling’ [47, 48] (Figure 3).




Figure 1. Domain structures of the Class II phosphoinositide 3-kinase (PI3K) isoforms.

PI3K-C2 α has a clathrin-binding domain (CBD) containing the clathrin box motif consensus sequence, whereas the N-terminal proline-rich region of PI3K-C2 β directly binds to the SH3 domain of intersectin-1 (ITSN) via its ITSN-binding domain. PI3K-C2 α also present a PX-domain that is responsible to the binding of PI(4,5)P2 in plasma membranes. C2, protein kinase C conserved region 2 (C2 domain), Catalytic, catalytic domain; CBD, clathrin-binding domain; Helical, helical domain; P, proline-rich region; PX, phox homology (PX domain). Ras, Ras-binding domain.

With respect to vascular endothelial cells, PI3K-C2 α is evidently involved in critical angiogenic signaling pathways via VEGF-A [12], S1P [13], TGF β 1 [14], and Notch1 (unpublished data) receptors. In PI3K-C2 α -deficient endothelial cells impaired receptor endocytosis results in various signaling defects; e.g. the impaired endosomal RhoA, Rac1, and Rap1 activation lead to defective VE-cadherin delivery to the cell–cell junction and subsequent defective adherence junction assembly [12]. It is therefore possible that PI3K-C2 α regulates the clathrin-mediated endocytosis that is highly integrated into signaling pathways, and in this regard several studies have demonstrated the existence of signaling-capable clathrin-coated structures on plasma membranes [49–51]. The endothelial function of PI3K-C2 α appears to be associated with its regulatory role in receptor endocytosis. The relevance of PI3K-C2 α in cancer biology has recently been demonstrated in studies in which the inactivation of PI3K-C2 α lead to delayed mitosis and subsequent reduced proliferation of breast cancer cells [52]. Surprisingly this process can serve a scaffold function that is not dependent on its kinase activity. The scaffold function of PI3K-C2 α may contribute to the alternative clathrin-dependent intracellular processes in which it regulates microtubule stabilization in kinetochore fibers during mitosis [53]. More detailed investigation is necessary to further elucidate the role of PI3K-C2 α in cancer progression.

Unlike PI3K-C2 α , the roles of PI3K-C2 β in the endocytic pathway are poorly understood; however, a critical role of the isoform in clathrin-mediated endocytosis has been reported. The multifunctional scaffold protein intersectin-1 has been identified as a binding partner of PI3K-C2 β via interaction between its SH3 domain and the proline-rich region of PI3K-C2 β [54]. A recent study demonstrated that the intersectin-1 also recruits the F-BAR domain-containing protein FCHSD2, which stimulates actin polymerization via activation of a WASP family protein, resulting in the formation of actin patches around the CCPs [55] (Figure 3). Cell migration is an actin remodeling-related cellular process that is also reportedly regulated by PI3K-C2 β [29, 40, 56, 57], suggesting that it may contribute to actin polymerization in the endocytic site via FCHSD2 recruitment. Consistent with this, we have demonstrated that the class II PI3K isoforms C2 α and C2 β , but not class I or III isoforms, are required for clathrin-dependent fluid-phase endocytosis ‘pinocytosis’ in endothelial cells [58].




Figure 2. Substrate specificity and subcellular localization of phosphoinositides produced by PI3K isoforms.

(A) Upstream activating input into distinct classes of PI3Ks and their downstream effector domains/proteins are shown. (B) Subcellular distribution of the distinct PI3K isoform-generated phosphoinositides is shown. The three classes of PI3K specifically generate sub-compartmentally localized 3'-phosphoinositide pools. Only PI(3,4,5)P3 is produced by class I PI3Ks in the plasma membrane, whereas both PI(3,4)P2 and PI(3)P are generated by class II and III PI3Ks, forming distinct cellular pools mainly involved in endo-lysosomal and autophagy pathways.

These observations indicate that PI3K-C2 α and PI3K-C2 β play different indispensable roles in clathrin-mediated endocytosis (Figure 3). Interestingly, PI3K-C2 β is also found to localize in late endosomes and lysosomes under starved conditions, where it suppresses the activity of mTORC1 [59]. A recent study demonstrated that protein kinase N regulates mTORC1 signaling by controlling PI3K-C2 β activity and localization [60], suggesting that functionally PI3K-C2 β counters the action of class I PI3K, which activates mTORC1. In addition, it has been demonstrated that the PI(3,4)P2 produced by PI3K-C2 γ regulates long-termed early endosomal Akt activation during insulin signaling [30]. Class II PI3K isoforms may therefore generate spatially distinct pools of PI(3)P or PI(3,4)P2, which are linked to endocytic events and endosomal signal transduction in a context-dependent manner (Figure 3), although several reports indicate that class II PI3Ks are involved in autophagy regulation [61–63].




Figure 3. Intracellular functions of the distinct class II PI3K isoforms.

PI3K-C2 α is recruited to clathrin-coated pits (CCPs) and clathrin-coated vesicles (CCVs) via direct binding to clathrin, and produces a local PI(3,4)P₂ pool. The PI3K-C2 α -mediated production of PI(3,4)P₂ triggers maturation of the CCPs and pinches off the neck of membrane invagination in cooperation with the sorting nexin-9 (SNX9), Arp2/3, and dynamin. Alternatively, PI3K-C2 α -mediated endocytic pools of PI(3)P facilitate endosomal signaling including RhoA, Rac1, and Rap1. PI3K-C2 β is also required for the formation and maturation of CCPs through its recruitment to CCPs via direct interaction with intersectin-1 (ITSN1). ITSN1 can recruit FCHSD2, which stimulates WASP-dependent actin filament formation at CCPs. PI3K-C2 β inhibits mTORC1 activation on late endosome/lysosome compartments under nutrient-starved conditions. In hepatocytes, PI3K-C2 γ mediates insulin-dependent production of endosomal PI(3,4)P₂ pools that can prolong endosomal Akt2 activation.

Distinct physiological roles of class II PI3K isoforms

The generation of PI3K-C2 α -targeted mice in 2012 [12] rapidly yielded insights into the physiological roles of class II PI3Ks at the organism level. Independently generated PI3K-C2 α knockout (KO) [37, 38, 64] or kinase-dead mutant [41] mice exhibit embryonic lethality at midgestation (E8.5 to 11.5), indicating that PI3K-C2 α has a non-redundant kinase-dependent role in murine development. PI3K-C2 α null-mice display significant roles in developmental angiogenesis and vascular barrier integrity [12], as well as primary cilia function [37]. Smooth muscle-specific and cardiomyocyte-specific deletion of PI3K-C2 α does not affect embryonic development or survival, but endothelial cell-specific deletion of PI3K-C2 α results in delayed death around E16.5–18.5, suggesting that unknown causes of death account for the observed embryonic lethality [12]. Although its postnatal physiological functions remain poorly understood, several studies implicate PI3K-C2 α in postnatal pathophysiology [12, 65, 41, 64]. A murine gene-trapped PI3K-C2 α mutant that expresses a truncated protein lacking a C-terminus is reportedly abnormally small and exhibits severe glomerulonephritis [65].

Heterozygous PI3K-C2 α -deficient mice develop normally and are fertile, and adults reportedly exhibit no obvious histological abnormalities in any organs examined [12, 64]. Notably, however, adult tamoxifen-inducible endothelial PI3K-C2 α conditional KO mice exhibit a greater incidence of severe dissecting aortic aneurysm formation in response to systemic infusion of angiotensin-II [12]. Pathophysiological defects are due to the impairment of vascular barrier integrity in mice with genetic loss of PI3K-C2 α . In other studies

investigating the therapeutic potential of targeting class II PI3Ks, in an *Mtm1*-deficient mouse model of X-linked myotubular myopathy, muscle-specific deletion of PI3K-C2 β , but not Vps34, can fully ameliorate their defective muscle morphology, reduce PI(3)P levels, and shortened survival [66]. X-linked myotubular myopathy is caused by mutations in the 3'-phosphatase *MTM1* gene that lead to impaired elimination of endosomal PI(3)P and result in defective endosomal trafficking. In contrast, PI3K-C2 β -null mice are reportedly normal and fertile [67, 68], indicating that PI3K-C2 β is not required for normal development.

Mountford J.K. et al. reported that heterozygous PI3K-C2 α (*Pik3c2a*^{+/-}) and homozygous PI3K-C2 β (*Pik3c2b*^{-/-}) double mutant mice are born at expected Mendelian ratios, exhibit no gross abnormalities, and have normal numbers of standard-sized platelets, although the constitutive knock-down of PI3K-C2 α resulted in altered platelet morphology and impaired membrane shear-dependent platelet adhesion [64, 69]. Notably however, smooth muscle cell-specific PI3K-C2 α deletion in PI3K-C2 β null background mice resulted in delayed parturition and reduced blood pressure due to impaired smooth muscle cell contraction in the uterus and blood vessels [15, 16], but this was not evident in mice with single KOs of each gene. This suggests that at least one isoform of class II PI3K-C2 α and PI3K-C2 β is essential for maintaining arterial blood pressure and normal parturition. It has been established that smooth muscle contraction is mediated by two major pathways, Ca²⁺-dependent myosin light-chain kinase activation, and small G-protein Rho and Rho-kinase-dependent myosin light-chain phosphatase (MLCP) inhibition [70–74]. In double KO cells the Rho pathway is inhibited and consequently MLCP activity is enhanced, suggesting that it leads to reduced contraction [15, 16].

The direct visualization of Rho activation in uterine myometrial cells [15] and aortic vascular smooth muscle cells [16] via using a Förster resonance energy transfer (FRET) imaging technique results in agonist-induced Rho activation, mainly in the early endosomes, and it is significantly reduced in double KO cells. Consistently, in previous studies the activation of endosomal small G-proteins including Rac1 and Rap1 was observed in vascular endothelial cells [12, 13], as was Rab11 activation [75]. This further emphasizes how class II PI3K-C2 α can regulate the endosomal signaling via modulation of receptor endocytosis. Ngok et al. [76] reported that the unique Rho-guanine nucleotide exchange factor (GEF) Syx is involved in endosomal Rho activation. It is possible that PI3K-C2 α facilitates receptor endocytosis and subsequent signaling in which ligand-bound receptors and their associated molecule Syx are assembled. Further investigation is necessary to identify a signaling molecule involved in endosomal signaling, and confirm its mechanistic roles.

Surprisingly, homozygous loss-of-function mutation of PI3K-C2 α has been reported in a small number of patients with a phenotype that skeletal abnormalities, short stature, cataract formation with glaucoma, and neurological manifestations [77], indicating a functional significance of PI3K-C2 α in humans. Cultured fibroblasts derived from these patients exhibit compensatory increases in PI3K-C2 β mRNA expression, raising the possibility of a compensatory mechanism similar to that observed in murine smooth muscle. The physiological significance and potential therapeutic implications of these observations remain to be determined.

Perspectives

- Three class II PI3K isoforms share functional roles in the regulation of vesicular trafficking events, and influence context-dependent specific cell signaling. Among them, PI3K-C2 α has a non-redundant role in clathrin-mediated endocytosis in mouse development.
- PI3K-C2 α and PI3K-C2 β play context-dependent compensatory or cooperative roles in smooth muscle tissues. Clathrin-mediated endocytosis is regulated by the class II PI3K isoforms PI3K-C2 α and PI3K-C2 β via distinct but at least partially redundant mechanisms, however the precise roles of three class II PI3K isoforms have not been elucidated.
- A full understanding of the physiological roles of three class II PI3K isoforms in vesicular trafficking remains a distant prospect. Knowledge pertaining to these roles and their impairment may provide insight into disease pathophysiology. A better understanding of these mechanisms requires faster live-cell imaging with super-resolution microscopy and quantitative microscopy to investigate spatio-temporal dynamics of phosphoinositide turnover mediated by class II PI3Ks.

Competing Interests

The author declares that there are no competing interests associated with this manuscript.

Acknowledgements

I thank Chiemi Hirose for secretarial assistance and was supported by grants from the Japan Society for the Promotion of Science [17K08532].

Abbreviations

Arp2/3, actin-related protein 2/3; C2, protein kinase C conserved region 2; CBD, clathrin-binding domain; CCP, clathrin-coated pit; CCV, clathrin-coated vesicle; FCHSD2, FCH and double SH3 domain 2; INPP, Inositol polyphosphate-1-phosphatase; ITSN1, intersectin-1; KO, knockout; mTORC1, mammalian target of rapamycin complex 1; PI, phosphoinositide; PX, phox homology; S1P, sphingosine-1-phosphate; SH3, src-homology 3; SNX, sorting nexin; TGF β 1, transforming growth factor- β 1; VEGF, vascular growth factor; Vps34, vacuolar protein sorting 3.

References

- 1 Schink, K.O., Tan, K.-W. and Stenmark, H. (2016) Phosphoinositides in control of membrane dynamics. *Annu. Rev. Cell Dev. Biol.* **32**, 143–171 <https://doi.org/10.1146/annurev-cellbio-111315-125349>
- 2 Bilanges, B., Posor, Y. and Vanhaesebroeck, B. (2019) PI3K isoforms in cell signaling and vesicle trafficking. *Nat. Rev. Mol. Cell Biol.* **20**, 515–534 <https://doi.org/10.1038/s41580-019-0129-z>
- 3 Fruman, D.A., Chiu, H., Hopkins, B.D., Bagrodia, S., Cantley, L.C., Abraham, R.T. (2017) The PI3K pathway in human disease. *Cell* **170**, 605–635 <https://doi.org/10.1016/j.cell.2017.07.029>
- 4 Backer, J.M. (2016) The intricate regulation and complex functions of the class III phosphoinositide 3-kinase Vps34. *Biochem. J.* **473**, 2251–2271 <https://doi.org/10.1042/BCJ20160170>
- 5 Mizushima, N. and Murphy, L.O. (2020) Autophagy assays for biological discovery and therapeutic development. *Trends Biochem. Sci.* **45**, 1080–1093 <https://doi.org/10.1016/j.tibs.2020.07.006>
- 6 Balla, T. (2013) Phosphoinositides: tiny lipids with giant impact on cell regulation. *Physiol. Rev.* **93**, 1019–1137 <https://doi.org/10.1152/physrev.00028.2012>
- 7 Bohdanowicz, M. and Grinstein, S. (2013) Role of phospholipids in endocytosis, phagocytosis and micropinocytosis. *Physiol. Rev.* **93**, 69–106 <https://doi.org/10.1152/physrev.00002.2012>
- 8 Redpath, G.M., Betzler, V.M., Rossatti, P. and Rossy, J. (2020) Membrane heterogeneity controls cellular endocytic trafficking. *Front. Cell Dev. Biol.* **8**, 757 <https://doi.org/10.3389/fcell.2020.00757>
- 9 Villasenor, R., Kalaidzidis, Y. and Zerial, M. (2016) Signal processing by the endosomal system. *Curr. Opin. Cell Biol.* **29**, 53–60 <https://doi.org/10.1016/j.ceb.2016.02.002>
- 10 Palfy, M., Remenyi, A. and Korcsmaros, T. (2012) Endosomal crosstalk: meeting points for signaling pathways. *Trends Cell Biol.* **22**, 447–456 <https://doi.org/10.1016/j.tcb.2012.06.004>
- 11 Mettlen, M., Chen, P.-H., Srinivasan, S., Danuser, G. and Schmid, S.L. (2018) Regulation of clathrin-mediated endocytosis. *Annu. Rev. Biochem.* **87**, 871–895 <https://doi.org/10.1146/annurev-biochem-062917-012644>
- 12 Yoshioka, K., Yoshida, K., Cui, H., Wakayama, T., Takuwa, N., Okamoto, Y. et al. (2012) Endothelial PI3K-C2 α , a class II PI3K, has an essential role in angiogenesis and vascular barrier function. *Nat. Med.* **18**, 1560–1569 <https://doi.org/10.1038/nm.2928>
- 13 Biswas, K., Yoshioka, K., Asanuma, K., Okamoto, Y., Takuwa, N., Sasaki, T. et al. (2013) Essential role of class II phosphatidylinositol-3-kinase-C2 α in sphingosine 1-phosphate receptor-1-mediated signaling and migration in endothelial cells. *J. Biol. Chem.* **288**, 2325–2339 <https://doi.org/10.1074/jbc.M112.409656>
- 14 Aki, S., Yoshioka, K., Okamoto, Y., Takuwa, N. and Takuwa, Y. (2015) Phosphatidylinositol 3-kinase class II α -isoform PI3K-C2 α is required for transforming growth factor β -induced smad signaling in endothelial cells. *J. Biol. Chem.* **290**, 6086–6105 <https://doi.org/10.1074/jbc.M114.601484>
- 15 Sarkar, M.A.K., Aki, S., Yoshioka, K., Kuno, K., Okamoto, Y., Ishimaru, K. et al. (2018) Class II PI3Ks α and β are required for Rho-dependent uterine smooth muscle contraction and parturition in mice. *Endocrinology* **160**, 235–248 <https://doi.org/10.1210/en.2018-00756>
- 16 Islam, S., Yoshioka, K., Aki, S., Ishimaru, K., Yamada, H., Takuwa, N. et al. (2019) Class II phosphatidylinositol 3-kinase α and β isoforms are required for vascular smooth muscle Rho activation, contraction and blood pressure regulation in mice. *J. Physiol. Sci.* **70**, 18 <https://doi.org/10.1186/s12576-020-00745-2>
- 17 Margaria, J.P., Ratto, E., Gozzelino, L. et al. (2019) Class II PI3Ks at the intersection between signal transduction and membrane trafficking. *Biomolecules* **9**, 104 <https://doi.org/10.3390/biom9030104>
- 18 Gulluni, F., De Santis, M.C., Margaria, J.P., Martini, M. and Hirsch, E. (2019) Class II PI3K functions in cell biology and disease. *Trends Cell Biol.* **29**, 339–359 <https://doi.org/10.1016/j.tcb.2019.01.001>
- 19 Wallroth, A. and Haucke, V. (2018) Phosphoinositide conversion in endocytosis and the endosomal system. *J. Biol. Chem.* **293**, 1526–1535 <https://doi.org/10.1074/jbc.R117.000629>
- 20 Burke, J.E. (2018) Structure basis for regulation of phosphoinositide kinases and their involvement in human diseases. *Mol. Cell* **71**, 653–673 <https://doi.org/10.1016/j.molcel.2018.08.005>
- 21 Dorman, G.L. and Burke, J.E. (2018) Molecular mechanisms of human disease mediated by oncogenic and primary immunodeficiency mutants in class IA phosphoinositide 3-kinases. *Front. Immunol.* **9**, 575 <https://doi.org/10.3389/fimmu.2018.00575>

- 22 Maffucci, T. and Falasca, M. (2014) New insight into the intracellular roles of class II phosphoinositide 3-kinases. *Biochem. Soc. Trans.* **42**, 1378–1382 <https://doi.org/10.1042/BST20140140>
- 23 Conduit, S.E. and Vanhaesebroeck, B. (2020) Phosphoinositide lipids in primary cilia biology. *Biochem. J.* **477**, 3541–3565 <https://doi.org/10.1042/BCJ20200277>
- 24 Virbasius, J.V., Guilherme, A. and Czech, M.P. (1996) Mouse p170 is a novel phosphatidylinositol 3-kinase containing a C2 domain. *J. Biol. Chem.* **271**, 13304–13307 <https://doi.org/10.1074/jbc.271.23.13304>
- 25 Domin, J., Pages, F., Volinia, S., Rittenhouse, S.E., Zvelebil, M.J., Stein, R.C. et al. (1997) Cloning of a human phosphoinositide 3-kinase with a C2 domain that display reduced sensitivity to the inhibitor wortmannin. *Biochem. J.* **326**, 139–147 <https://doi.org/10.1042/bj3260139>
- 26 Wang, Y., Yoshioka, K., Azam, M.A., Takuwa, N., Sakurada, S., Kayaba, Y. et al. (2006) Class II phosphoinositide 3-kinase α -isoform regulates Rho, myosin phosphatase and contraction in vascular smooth muscle. *Biochem. J.* **394**, 581–592 <https://doi.org/10.1042/BJ20051471>
- 27 Yoshioka, K., Sugimoto, N., Takuwa, N. and Takuwa, Y. (2007) Essential role for class II phosphoinositide 3-kinase α -isoform in Ca^{2+} -induced, Rho- and Rho kinase-dependent regulation of myosin phosphatase and contraction in isolated vascular smooth muscle cells. *Mol. Pharmacol.* **71**, 912–920 <https://doi.org/10.1124/mol.106.032599>
- 28 Rozycka, M., Lu, Y.J., Brown, R.A., Lau, M.R., Shipley, J.M. and Fry, M.J. (1998) cDNA cloning of third human C2 domain-containing class II phosphoinositide 3-kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 12p12. *Genomics* **54**, 569–574 <https://doi.org/10.1006/geno.1998.5621>
- 29 Maffucci, T., Cooke, F.T., Foster, F.M., Traer, C.J., Fry, M.J., Falasca, M. (2005) Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. *J. Cell. Biol.* **169**, 789–799 <https://doi.org/10.1083/jcb.200408005>
- 30 Braccini, L., Ciralo, E., Campa, C.C., Perino, A., Longo, D.L., Tibolla, G. (2015) PI3K-C2y is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. *Nat. Commun.* **6**, 7400 <https://doi.org/10.1038/ncomms8400>
- 31 Chen, K.-E., Vikas, A., Tillu, V.A., Chandra, M. and Collins, B.M. (2018) Molecular basis for membrane recruitment by the PX and C2 domains of class II phosphoinositide 3-kinase-C2 α . *Structure* **26**, 1612–1625 <https://doi.org/10.1016/j.str.2018.08.010>
- 32 Wang, H., Lo, W.-T., Žagar, A.V., Gulluni, F., Lehmann, M., Scapozza, L. (2018) Autoregulation of class II alpha PI3K activity by its lipid-binding PX-C2 domain module. *Mol. Cell* **71**, 343–351 <https://doi.org/10.1016/j.molcel.2018.06.042>
- 33 Domin, J., Gaidarov, I., Smith, M.E., Keen, J.H. and Waterfield, M.D. (2000) The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles. *J. Biol. Chem.* **275**, 11943–11950 <https://doi.org/10.1074/jbc.275.16.11943>
- 34 Dell'Angelica, E.C., Klumperman, J., Stoorvogeland, W. and Bonifacino, J.S. (1998) Association of the AP-3 adaptor complex with clathrin. *Science* **280**, 431–434 <https://doi.org/10.1126/science.280.5362.431>
- 35 Dell'Angelica, E.C. (2001) Clathrin-binding proteins: Got a motif? *Join the network! Trends Cell Biol.* **11**, 315–318 [https://doi.org/10.1016/S0962-8924\(01\)02043-8](https://doi.org/10.1016/S0962-8924(01)02043-8)
- 36 Wheeler, M. and Domin, J. (2006) The N-terminus of phosphoinositide 3-kinase-C2 β regulates lipid kinase activity and binding to clathrin. *J. Cell. Physiol.* **206**, 586–593 <https://doi.org/10.1002/jcp.20507>
- 37 Franco, I., Gulluni, F., Campa, C.C., Costa, C., Margaria, J.P., Ciralo, E. et al. (2014) PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. *Dev. Cell* **28**, 647–658 <https://doi.org/10.1016/j.devcel.2014.01.022>
- 38 Posor, Y., Eichhorn-Gruenig, M., Puchkov, D., Schöneberg, J., Ullrich, A., Lampe, A. et al. (2013) Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate. *Nature* **499**, 233–237 <https://doi.org/10.1038/nature12360>
- 39 Banfic, H., Viskic, D., Mise, D., Balakrishnan, S., Deplano, S., Korchev, Y.E. et al. (2009) Epidermal growth factor stimulates translocation of the class II phosphoinositide 3-kinase PI3K-C2beta to the nucleus. *Biochem. J.* **422**, 53–60 <https://doi.org/10.1042/BJ20090654>
- 40 Domin, J., Harper, L., Aubyn, D., Balakrishnan, S., Deplano, S., Korchev, Y.E. et al. (2005) The phosphoinositide 3-kinase PI3K-C2beta regulates cell migration by a PtdIns3P dependent mechanism. *J. Cell Physiol.* **205**, 452–462 <https://doi.org/10.1002/jcp.20478>
- 41 Alliouachene, S., Bilangas, B., Chaussade, C., Pearce, W., Foukas, L.C., Scudamore, C.L. et al. (2016) Inactivation of class II PI3K-C2 α induces leptin resistance, age-dependent insulin resistance and obesity in male mice. *Diabetologia* **59**, 1503–1512 <https://doi.org/10.1007/s00125-016-3963-y>
- 42 Aki, S., Yoshioka, K., Takuwa, N. and Takuwa, Y. (2020) TGF β receptor endocytosis and Smad signaling require synaptojanin1-, PI3K-C2 α -, and INPP4B mediated phosphoinositide conversions. *Mol. Biol. Cell* **31**, 360–372 <https://doi.org/10.1091/mbc.E19-11-0662>
- 43 Lo, W.-T., Žagar, A. V., Gerth, S., Lehmann, M., Puchkov, D., Krylova, O. (2017) A coincidence detection mechanism controls PX-BAR domain-mediated endocytic membrane remodeling via an allosteric structural switch. *Dev. Cell* **43**, 522–529 <https://doi.org/10.1016/j.devcel.2017.10.019>
- 44 Schöneberg, J., Lehmann, M., Ullrich, A., Posor, Y., Lo, W.-T., Lichtner, G. et al. (2017) Lipid-mediated PX-BAR domain recruitment couples local membrane constriction to endocytic vesicle fission. *Nat. Commun.* **8**, 15873 <https://doi.org/10.1038/ncomms15873>
- 45 Shin, N., Ahn, N., Chang-Ileto, B., Park, J., Takei, K., Ahn, S. et al. (2008) SNX9 regulates tubular invagination of the plasma membrane through interaction with actin cytoskeleton and dynamin 2. *J. Cell. Sci.* **121**, 1252–1263 <https://doi.org/10.1242/jcs.016709>
- 46 Ferguson, S., Raimondi, A., Paradise, S., Shen, H., Mesaki, K., Ferguson, A. et al. (2009) Coordinated actions of actin and BAR proteins upstream of dynamin at endocytic clathrin-coated pits. *Dev. Cell* **17**, 811–822 <https://doi.org/10.1016/j.devcel.2009.11.005>
- 47 Miaczynska, M., Pelkmans, L. and Zerial, M. (2004) Not just a sink: endosomes in control of signal transduction. *Curr. Opin. Cell Biol.* **16**, 400–406 <https://doi.org/10.1016/j.ceb.2004.06.005>
- 48 Le Roy, C. and Wrana, J.L. (2005) Clathrin- and non-clathrin-mediated endocytic regulation of cell signaling. *Nat. Rev. Mol. Cell Biol.* **6**, 112–126 <https://doi.org/10.1038/nrm1571>
- 49 Garay, C., Judge, G., Lucarelli, S., Bautista, S., Pandey, R., Singh, T. et al. (2015) Epidermal growth factor-stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis. *Mol. Biol. Cell* **26**, 3504–3519 <https://doi.org/10.1091/mbc.E14-09-1412>
- 50 Rosselli-Murai, L.K., Yates, J.A., Yoshida, S., Bourg, J., Ho, K.K.Y., White, M. et al. (2018) Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. *J. Cell Sci.* **131**, jcs208926 <https://doi.org/10.1242/jcs.208926>
- 51 Eichel, K., Jullie, D., Barsi-Rhyne, B., Latorraca, N.R., Masuree, M., Sibarita, J.-B. et al. (2018) Catalytic activation of b-arrestin by GPCRs. *Nature* **557**, 381–386 <https://doi.org/10.1038/s41586-018-0079-1>
- 52 Gulluni, F., Martini, M., DeSantis, M., Campa, C.C., Ghigo, A., Margaria, J.P. et al. (2017) Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2 α scaffold function. *Cancer Cell* **32**, 444–459 <https://doi.org/10.1016/j.ccell.2017.09.002>

- 53 Royle, S.J. (2013) Protein adaptation: mitotic functions for membrane trafficking proteins. *Nat. Rev. Mol. Cell Biol.* **14**, 592–559 <https://doi.org/10.1038/nrm3641>
- 54 Russo, A. and O'Bryan, J.O. (2012) Intersectin 1 is required for neuroblastoma tumorigenesis. *Oncogene* **31**, 4828–4834 <https://doi.org/10.1038/onc.2011.643>
- 55 Almeida-Souza, L., Frank, R.A.W., Garcia-Nafria, J., Colussi, A., Gunawardana, N., Johnson, C.M. et al. (2018) A flat BAR protein promotes actin polymerization at the base of clathrin-coated pits. *Cell* **174**, 325–337 <https://doi.org/10.1016/j.cell.2018.05.020>
- 56 Katso, R.M., Pardo, O.E., Palamidessi, A., Reanz, C.M., Marinov, M., De Laurentis, A. et al. (2006) Phosphoinositide 3-Kinase C2 β regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. *Mol. Biol. Cell* **17**, 3729–3744 <https://doi.org/10.1091/mbc.E05-11-1083>
- 57 Mooren, O.L., Galletta, B.J. and Cooper, J.A. (2012) Roles for actin assembly in endocytosis. *Annu. Rev. Biochem.* **81**, 661–686 <https://doi.org/10.1146/annurev-biochem-060910-094416>
- 58 Aung, K.T., Yoshioka, K., Aki, S., Ishimaru, K., Takuwa, N. and Takuwa, Y. (2019) The class II phosphoinositide 3-kinases PI3K-C2 α and PI3K-C2 β differentially regulate clathrin-dependent pinocytosis in human vascular endothelial cells. *J. Physiol. Sci.* **69**, 263–280 <https://doi.org/10.1007/s12576-018-0644-2>
- 59 Marat, A.L., Wallroth, A., Lo, W.T., Muller, R., Norata, G.D., Falasca, M. et al. (2017) mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate. *Science* **356**, 968–972 <https://doi.org/10.1126/science.aaf8310>
- 60 Wallroth, A., Koch, P.A., Marat, A.L., Krause, E. and Haucke, V. (2019) Protein kinase N controls a lysosomal lipid switch to facilitate nutrient signaling via mTORC1. *Nat. Cell Biol.* **21**, 1093–1101 <https://doi.org/10.1038/s41556-019-0377-3>
- 61 Devereaux, K., Dall'Armi, C., Alcazar-Roman, A., Ogasawara, Y., Zhou, X., Wang, F. et al. (2013) Regulation of mammalian autophagy by class II and III PI 3-kinases through PI3P synthesis. *PLoS One* **8**, e76405 <https://doi.org/10.1371/journal.pone.0076405>
- 62 Lu, N., Shen, Q., Mahoney, T.R., Neukomm, L.J., Wang, Y. and Zhou, Z. (2012) Two PI 3-kinases and one PI 3-phosphatase together establish the cyclic waves of phagosomal PtdIns(3)P critical for the degradation of apoptotic cells. *PLoS Biol.* **10**, e1001245 <https://doi.org/10.1371/journal.pbio.1001245>
- 63 Merrill, N.M., Schipper, J., Karnes, J.B., Kauffman, A.L., Martin, K.R. and MacKeigan, J.P. (2017) PI3K-C2 α knockdown decreases autophagy and maturation of endocytic vesicles. *PLoS One* **12**, e0184909 <https://doi.org/10.1371/journal.pone.0184909>
- 64 Mountford, J.K., Petitjean, C., Putra, H.W.K., McCafferty, J.A., Setiabakti, N.M., Lee, H. et al. (2015) The class II PI 3-kinase, PI3KC2 α , links platelet internal membrane structure to shear-dependent adhesive function. *Nat Commun.* **6**, 6535 <https://doi.org/10.1038/ncomms7535>
- 65 Harris, D.P., Vogel, P., Wims, M., Moberg, K., Humphries, J., Jhaver, K.G. et al. (2011) Requirement for class II phosphoinositide 3-kinase C2alpha in maintenance of glomerular structure and functions. *Mol. Cell Biol.* **31**, 63–80 <https://doi.org/10.1128/MCB.00468-10>
- 66 Sabha, N., Volpatti, J.R., Gonorazky, H., Reifler, A., Davidson, A.E., Li, X. et al. (2016) PIK3C2 β inhibition improves function and prolongs survival in myotubular myopathy animal models. *J. Clin. Invest.* **126**, 3613–3625 <https://doi.org/10.1172/JCI86841>
- 67 Alliouachene, S., Bilanges, B., Chicanne, G., Anderson, K.E., Pearce, W., Ali, K. et al. (2015) Inactivation of the class II PI3K-C2 β potentiates insulin signaling and sensitivity. *Cell Rep.* **13**, 1881–1894 <https://doi.org/10.1016/j.celrep.2015.10.052>
- 68 Harada, K., Truong, A.B., Cai, T. and Khavari, P.A. (2005) The class II phosphoinositide 3-kinase C2beta is not essential for epidermal differentiation. *Mol. Cell Biol.* **25**, 11122–11130 <https://doi.org/10.1128/MCB.25.24.11122-11130.2005>
- 69 Valet, C., Chicanne, G., Severac, C., Chaussade, C., Whitehead, M.A., Cabou, C. et al. (2015) Essential role of class II PI3K-C2 α in platelet membrane morphology. *Blood* **126**, 1128–1137 <https://doi.org/10.1182/blood-2015-03-636670>
- 70 Azam, M.A., Yoshioka, K., Ohkura, S., Takuwa, N., Sugimoto, N., Sato, K. et al. (2007) Ca²⁺-independent, inhibitory effects of cyclic adenosine 5'-monophosphate on Ca²⁺ regulation of phosphoinositide 3-kinase C2 α , Rho, and myosin phosphatase in vascular smooth muscle. *J. Pharmacol. Exp. Ther.* **320**, 907–916 <https://doi.org/10.1124/jpet.106.111443>
- 71 Seok, Y.M., Azam, M.A., Okamoto, Y., Sato, A., Yoshioka, K., Maeda, M. et al. (2010) Enhanced Ca²⁺-dependent activation of phosphoinositide 3-kinase class II α isoform-Rho axis in blood vessels of spontaneously hypertensive rats. *Hypertension* **56**, 934–941 <https://doi.org/10.1161/HYPERTENSIONAHA.110.160853>
- 72 Sakurada, S., Okamoto, H., Takuwa, N., Sugimoto, N. and Takuwa, Y. (2001) Rho activation in excitatory agonist-stimulated vascular smooth muscle. *Am. J. Physiol. Cell Physiol.* **281**, 571–578 <https://doi.org/10.1152/ajpcell.2001.281.2.C571>
- 73 Sakurada, S., Takuwa, N., Sugimoto, N., Wang, Y., Seto, M., Sasaki, Y. et al. (2003) Ca²⁺-dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. *Circ. Res.* **93**, 548–556 <https://doi.org/10.1161/01.RES.0000090998.08629.60>
- 74 Somlyo, A.P. and Somlyo, A.V. (2003) Ca²⁺-sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, and myosin phosphatase. *Physiol. Rev.* **83**, 1325–1358 <https://doi.org/10.1152/physrev.00023.2003>
- 75 Campa, C.C., Margarita, J.P., Derle, A., Giudice, M.D., De Santis, M.C., Gozzelino, L. et al. (2018) Rab11 activity and ptdIns(3)P turnover removes recycling cargo from endosomes. *Nat. Chem. Biol.* **14**, 801–810 <https://doi.org/10.1038/s41589-018-0086-4>
- 76 Ngok, S.P., Geyer, R., Liu, M., Kourtidis, A., Agrawal, S., Wu, C. et al. (2012) VEGF and angiotensin-1 exert opposing effects on cell junctions by regulating the Rho GEF Syx. *J. Cell Biol.* **199**, 1103–1115 <https://doi.org/10.1083/jcb.201207009>
- 77 Tiosano, D. (2019) Mutations in *PIK3C2A* cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction. *PLoS Genet.* **15**, e1008088 <https://doi.org/10.1371/journal.pgen.1008088>